140 related articles for article (PubMed ID: 36521561)
1. In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
Mohnicke M; Blecher A; Beichert K; Bidlingmaier B; Todt EJ; Dette C; Rotthaeuser B; Mukherjee B
J Pharm Sci; 2023 Apr; 112(4):963-973. PubMed ID: 36521561
[TBL] [Abstract][Full Text] [Related]
2. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Thrasher J; Polsky S; Hovsepian L; Nowotny I; Pierre S; Bois De Fer B; Bhargava A; Mukherjee B; Garg SK
Diabetes Technol Ther; 2020 Sep; 22(9):666-673. PubMed ID: 31833801
[No Abstract] [Full Text] [Related]
3. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump.
Senstius J; Harboe E; Westermann H
Diabetes Technol Ther; 2007 Feb; 9(1):75-9. PubMed ID: 17316101
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
6. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
7. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial.
Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
Diabetes Obes Metab; 2024 Feb; 26(2):540-547. PubMed ID: 37880868
[TBL] [Abstract][Full Text] [Related]
8. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
DeFelippis MR; Bell MA; Heyob JA; Storms SM
Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.
Senstius J; Poulsen C; Hvass A
Diabetes Technol Ther; 2007 Dec; 9(6):517-21. PubMed ID: 18034606
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects.
Shiramoto M; Yoshihara T; Schmider W; Takagi H; Nowotny I; Kajiwara M; Muto H
Sci Rep; 2021 Nov; 11(1):22931. PubMed ID: 34824344
[TBL] [Abstract][Full Text] [Related]
11. 14-day in vitro chemical stability of insulin lispro in the MiniMed Paradigm pump.
Sharrow SD; Glass LC; Dobbins MA
Diabetes Technol Ther; 2012 Mar; 14(3):264-70. PubMed ID: 22107252
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.
Shah VN; Franek E; Wernicke-Panten K; Pierre S; Mukherjee B; Sadeharju K
Diabetes Ther; 2021 Feb; 12(2):557-568. PubMed ID: 33432547
[TBL] [Abstract][Full Text] [Related]
13. A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Mukherjee B; Nowotny I
Diabetes Obes Metab; 2021 Mar; 23(3):674-681. PubMed ID: 33236518
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Zijlstra E; Demissie M; Graungaard T; Heise T; Nosek L; Bode B
J Diabetes Sci Technol; 2018 Jan; 12(1):145-151. PubMed ID: 28918652
[TBL] [Abstract][Full Text] [Related]
15. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.
Weinzimer SA; Ternand C; Howard C; Chang CT; Becker DJ; Laffel LM;
Diabetes Care; 2008 Feb; 31(2):210-5. PubMed ID: 17989308
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
Bode BW
Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
[TBL] [Abstract][Full Text] [Related]
18. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
[TBL] [Abstract][Full Text] [Related]
19. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
